$6.15
2.46% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$6.30
-3.29 34.31% 1M
-1.97 23.82% 6M
-1.80 22.22% YTD
+2.22 54.41% 1Y
+0.71 12.70% 3Y
+3.22 104.55% 5Y
-39.10 86.12% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.23 3.79%
ISIN
US21900C3088
Symbol
CRMD
Sector

Key metrics

Market capitalization $410.65m
Enterprise Value $359.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.27
P/S ratio (TTM) P/S ratio 9.45
P/B ratio (TTM) P/B ratio 4.79
Revenue (TTM) Revenue $43.47m
EBIT (operating result TTM) EBIT $-22.36m
Free Cash Flow (TTM) Free Cash Flow $-50.73m
Cash position $51.69m
EPS (TTM) EPS $-0.33
P/E forward 21.00
P/S forward 3.31
EV/Sales forward 2.90
Short interest 13.49%
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CorMedix Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a CorMedix Inc forecast:

Buy
100%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
43 43
-
100%
- Direct Costs 3.19 3.19
1,419% 1,419%
7%
40 40
19,281% 19,281%
93%
- Selling and Administrative Expenses 58 58
65% 65%
134%
- Research and Development Expense 3.94 3.94
70% 70%
9%
-22 -22
55% 55%
-50%
- Depreciation and Amortization 0.46 0.46
119% 119%
1%
EBIT (Operating Income) EBIT -22 -22
54% 54%
-51%
Net Profit -18 -18
61% 61%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Neutral
GlobeNewsWire
one day ago
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025.
Positive
Seeking Alpha
6 days ago
CorMedix Inc.'s DefenCath, FDA-approved in Q4 2023, effectively prevents catheter-related bloodstream infections in hemodialysis patients, showing 71% efficacy compared to competitors. Despite recent profitability and strong market potential, the stock price has increased post-FDA approval, making it appropriately priced for its risk level. Key risks include adoption speed, supply chain scalabi...
Neutral
GlobeNewsWire
7 days ago
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) on behalf of CorMedix stockholders. Our investigation concerns whether CorMedix has violated the federal securities laws and/or engaged in other unlawful business practi...
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 65
Founded 2006
Website www.cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today